[Treatment of patients with destructive arthritis with certolizumab pegol]. / Therapie mit Certolizumab pegol bei Patienten mit destruierender Arthritis.

ABSTRACT

Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. Due to the modification of the antibody fragment by the adherence of polyethylene glycol (PEG) a sufficient distribution in inflammatory tissue was found in animal experiments. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol.